Literature DB >> 8642370

Diagnosing and treating onychomycosis.

N Zaias1, B Glick, G Rebell.   

Abstract

Onychomycosis is a persistent fungal infection of the toenails or fingernails that is usually not painful but is unsightly and can affect a patient's quality of life by interfering with footwear. It may affect up to 30% of the population by age 60. In more that 99% of cases, it is caused by dermatophytes, the most common of which are Trichophyton rubrum and Trichophyton mentagrophytes. Each of the four clinical types of onychomycosis, as defined by the route of fungal invasion, has a characteristic appearance, but other diseases, particularly psoriasis, may have a similar appearance. Proper management, therefore, includes confirmation of fungal infection by potassium hydroxide slide preparation and culture. Traditionally, pharmacologic treatment has been less than optimal. In many cases, griseofulvin, the first oral agent approved for onychomycosis in the United States, must be given for 1 year or more to be effective. Low cure rates are related to poor bioavailability and the fungistatic rather than fungicidal effect of the drug. Newer agents, such as oral itraconazole and oral terbinafine, promise to substantially increase cure rates while shortening treatment duration. Oral terbinafine is potently fungicidal against dermatophytes and has proven efficacious with regimens as brief as 12 weeks when the nail is not 100% involved.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8642370

Source DB:  PubMed          Journal:  J Fam Pract        ISSN: 0094-3509            Impact factor:   0.493


  11 in total

Review 1.  Which antifungal agent for onychomycosis? A pharmacoeconomic analysis.

Authors:  V N Joish; E P Armstrong
Journal:  Pharmacoeconomics       Date:  2001       Impact factor: 4.981

2.  Measuring the impact of onychomycosis on patient quality of life.

Authors:  R R Turner; M A Testa
Journal:  Qual Life Res       Date:  2000-02       Impact factor: 4.147

3.  Onychomycosis Associated with Superficial Skin Infection Due to Aspergillus sydowii in an Immunocompromised Patient.

Authors:  Parismita Borgohain; Purnima Barua; Pranjal Jyoti Dutta; Dipika Shaw; Shivaprakash M Rudramurthy
Journal:  Mycopathologia       Date:  2019-09-09       Impact factor: 2.574

4.  SIXTEEN YEARS OF DERMATOMYCOSIS CAUSED BY Candida spp. IN THE METROPOLITAN AREA OF PORTO ALEGRE, SOUTHERN BRAZIL.

Authors:  Daiane Heidrich; Cheila Denise Ottonelli Stopiglia; Cibele Massotti Magagnin; Tatiane Caroline Daboit; Gerson Vettorato; Taís Guarienti Amaro; Maria Lúcia Scroferneker
Journal:  Rev Inst Med Trop Sao Paulo       Date:  2016-03-22       Impact factor: 1.846

Review 5.  Onychomycosis: pathogenesis, diagnosis, and management.

Authors:  B E Elewski
Journal:  Clin Microbiol Rev       Date:  1998-07       Impact factor: 26.132

6.  Study of the Etiological Causes of Toe Web Space Lesions in Cairo, Egypt.

Authors:  Hussein Mohamed Hassab-El-Naby; Yasser Fathy Mohamed; Hamed Mohamed Abdo; Mohamed Ismail Kamel; Wael Refaat Hablas; Osama Khalil Mohamed
Journal:  Dermatol Res Pract       Date:  2015-09-21

7.  Onychomycosis due to opportunistic molds.

Authors:  Erick Obed Martínez-Herrera; Stefanie Arroyo-Camarena; Diana Luz Tejada-García; Carlos Francisco Porras-López; Roberto Arenas
Journal:  An Bras Dermatol       Date:  2015-06-01       Impact factor: 1.896

8.  Use of restriction fragment length polymorphism to identify Candida species, related to onychomycosis.

Authors:  Rasoul Mohammadi; Parisa Badiee; Hamid Badali; Mahdi Abastabar; Ahmad Hosseini Safa; Mahboubeh Hadipour; Hajar Yazdani; Farnaz Heshmat
Journal:  Adv Biomed Res       Date:  2015-05-11

9.  A Case of Onychomycosis Caused by Rhodotorula glutinis.

Authors:  Hatice Uludag Altun; Tuba Meral; Emel Turk Aribas; Canan Gorpelioglu; Nilgun Karabicak
Journal:  Case Rep Dermatol Med       Date:  2014-09-25

Review 10.  The Dermatologist's Approach to Onychomycosis.

Authors:  Jenna N Queller; Neal Bhatia
Journal:  J Fungi (Basel)       Date:  2015-08-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.